Drug
BMS-813160 clinical trials
Also written BMS-813160.
- studies test it
- 6
- open now
- 0
- in phase 3
- 0
- first study started
- 2010
How studies write it
Studies that test it under each name
Development codes
Studies by the year they started
6 studies that test it; most in 2017 (2)
| Year | Studies |
|---|---|
| 2010 | 1 |
| 2013 | 1 |
| 2017 | 2 |
| 2018 | 1 |
| 2020 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 3
- Phase 2
- 5
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 4 · Other 2
Bristol-Myers Squibb (4) · Icahn School of Medicine at Mount Sinai (1) · Washington University School of Medicine (1)
Often tested with
Tested in the same studies.
Nivolumab (2) · HuMax-IL8 (1) · Albumin-Bound Paclitaxel (1) · Paclitaxel (1) · Gemcitabine (1) · Fluorouracil (1) · Leucovorin (1) · Irinotecan (1)
Studies
Open first, then newest update. How each study uses BMS-813160 is read from its arms, and is right about nine times in ten.
Testing it · 6
- Neoadjuvant Nivolumab With CCR2/5-inhibitor or Anti-IL-8) for Non-small Cell Lung Cancer (NSCLC) or Hepatocellular Carcinoma (HCC)Active, not recruitingPhase 2Icahn School of Medicine at Mount SinaiNCT04123379Written as BMS-813160
- A Study of BMS-813160 in Combination With Chemotherapy or Nivolumab in Participants With Advanced Solid TumorsCompletedPhase 1/2Bristol-Myers SquibbNCT03184870Written as BMS-813160
- BMS-813160 With Nivolumab and Gemcitabine and Nab-paclitaxel in Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma (PDAC)CompletedPhase 1/2Washington University School of MedicineNCT03496662Written as BMS-813160
- A Study to Test Combination Treatments in People With Advanced Renal Cell CarcinomaCompletedPhase 2Bristol-Myers SquibbNCT02996110Written as BMS-813160
- Study to Evaluate the Effects of BMS-813160 on Protein Loss in the Urine of Subjects With Type 2 Diabetes and Diabetic Kidney DiseaseTerminatedPhase 2Bristol-Myers SquibbNCT01752985Written as BMS-813160
- Single Ascending Dose (BMS-813160) StudyCompletedPhase 1Bristol-Myers SquibbNCT01049165Written as BMS-813160
Given in every arm · 1 — BMS-813160 is usual care beside what is tested
Codes
What other systems call BMS-813160 · ClinicalTrials.gg INT006011
- MeSH (NLM) C570874BMS-813160One source ClinicalTrials.gov
- UNII (FDA) 83U7957287BMS-813160One source FDA
- NCI Thesaurus C139550CCR2/CCR5 Antagonist BMS-813160One source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C570874 | BMS-813160 | One source ClinicalTrials.gov |
| UNII (FDA) | 83U7957287 | BMS-813160 | One source FDA |
| NCI Thesaurus | C139550 | CCR2/CCR5 Antagonist BMS-813160 | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.